Research News and Research

RSS

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Alcon reports 2009 fourth quarter results

Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.

11 Feb 2010

AMA unhappy with Senate plan for Medicare 'doc fix'

The American Medical Association is criticizing "a Senate plan for avoiding a proposed 21 percent cut in government payments to physicians who treat the elderly, calling the proposal a 'Band-Aid' measure," Bloomberg/BusinessWeek reports.

11 Feb 2010

Cognitive behavioral therapy effective for insomnia and chronic pain

Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.

11 Feb 2010

Study suggests obesity prevention efforts should begin much earlier

While many adults consider a chubby baby healthy, too many plump infants grow up to be obese teens, saddling them with Type-2 diabetes, elevated cholesterol and high blood pressure, according to an article published this month in the journal Clinical Pediatrics (published by SAGE).

11 Feb 2010

RadPharm and Medifacts International announce merger

RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, today announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.

11 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

PHC announces second-quarter fiscal 2010 results

PHC, Inc., d/b/a Pioneer Behavioral Health, “Pioneer” or (the “Company”), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company's 2010 second fiscal quarter ended December 31, 2009. The results exclude the operations of the Company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation.

11 Feb 2010

Arrowhead Research reports revenue of $148,000 for quarter ended December 31, 2009

Arrowhead Research Corporation today announced financial results for its fiscal 2010 first quarter ended December 31, 2009.

11 Feb 2010

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Boston Scientific Corporation today announced a series of management changes and restructuring initiatives designed to strengthen the Company and position it for long-term success.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

First Edition: February 11, 2010

Today's headlines raise interesting questions for health reform, including whether Sen. Judd Gregg can play an important role in finding bipartisanship.

11 Feb 2010

DuPont Agriculture & Nutrition segment expected to grow by 10% in 2010, says James C. Borel

DuPont Executive Vice President James C. Borel said he expects the DuPont Agriculture & Nutrition segment to grow sales by 10 percent in 2010 and increase pre-tax operating income margin across the seed, crop protection, and nutrition and health businesses.

11 Feb 2010

Neurotoxin study may help find new therapies to block hyperactive ion channels

There are approximately 500 species of cone snails, each producing 50 - 200 different conotoxins. A similar number of peptide toxins are produced by snakes, spiders, sea anemones, scorpions and other venomous animals. The animals use the neurotoxins to paralyze their prey.

11 Feb 2010

$NovaShunt initiates study to evaluate AFS for refractory ascites patients$

NovaShunt initiates study to evaluate AFS for refractory ascites patients

NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.

11 Feb 2010

Altarum Institute re-vamps Health Policy Forum “blog” for 2010

Altarum Institute, a nonprofit health systems research and consulting organization, has re-vamped its Health Policy Forum “blog” for 2010. With a fresh look and new content, the blog is now tailored to the interests of journalists and health policy experts looking for thought-provoking commentary and analysis of the most pressing issues in health care today.

11 Feb 2010

hESC and iPSC: Long-term stem cell evaluation and comparison study

For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.

11 Feb 2010

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on methamphetamine dependent subjects were published in the Journal of Psychopharmacology, a peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology.

11 Feb 2010

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

Cancer Research UK scientists have identified the frequency of new genetic 'hotspots' which could help doctors to tailor therapies to as many as 3,000 additional bowel cancer patients each year, according to research published in the British Journal of Cancer today.

11 Feb 2010

Research News and Research

FDA grants approval for Abbott's antiretroviral medication Norvir

Alcon reports 2009 fourth quarter results

AMA unhappy with Senate plan for Medicare 'doc fix'

Cognitive behavioral therapy effective for insomnia and chronic pain

Study suggests obesity prevention efforts should begin much earlier

RadPharm and Medifacts International announce merger

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

PHC announces second-quarter fiscal 2010 results

Arrowhead Research reports revenue of $148,000 for quarter ended December 31, 2009

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

First Edition: February 11, 2010

DuPont Agriculture & Nutrition segment expected to grow by 10% in 2010, says James C. Borel

Neurotoxin study may help find new therapies to block hyperactive ion channels

NovaShunt initiates study to evaluate AFS for refractory ascites patients

Altarum Institute re-vamps Health Policy Forum “blog” for 2010

hESC and iPSC: Long-term stem cell evaluation and comparison study

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring